CMPDA

CAS# 380607-77-2

CMPDA

Catalog No. BCC6151----Order now to get a substantial discount!

Product Name & Size Price Stock
CMPDA: 5mg $92 In Stock
CMPDA: 10mg Please Inquire In Stock
CMPDA: 20mg Please Inquire Please Inquire
CMPDA: 50mg Please Inquire Please Inquire
CMPDA: 100mg Please Inquire Please Inquire
CMPDA: 200mg Please Inquire Please Inquire
CMPDA: 500mg Please Inquire Please Inquire
CMPDA: 1000mg Please Inquire Please Inquire
Related Products
  • PF-4708671

    Catalog No.:BCC5031
    CAS No.:1255517-76-0
  • BIX 02565

    Catalog No.:BCC4303
    CAS No.:1311367-27-7
  • BI-D1870

    Catalog No.:BCC5030
    CAS No.:501437-28-1
  • FMK

    Catalog No.:BCC1580
    CAS No.:821794-92-7

Quality Control of CMPDA

Number of papers citing our products

Chemical structure

CMPDA

3D structure

Chemical Properties of CMPDA

Cas No. 380607-77-2 SDF Download SDF
PubChem ID 9969799 Appearance Powder
Formula C16H28N2O4S2 M.Wt 376.53
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 100 mg/mL (265.58 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name N-[2-[4-[2-(propan-2-ylsulfonylamino)ethyl]phenyl]ethyl]propane-2-sulfonamide
SMILES CC(C)S(=O)(=O)NCCC1=CC=C(C=C1)CCNS(=O)(=O)C(C)C
Standard InChIKey FHLGMMYEKXPVSC-UHFFFAOYSA-N
Standard InChI InChI=1S/C16H28N2O4S2/c1-13(2)23(19,20)17-11-9-15-5-7-16(8-6-15)10-12-18-24(21,22)14(3)4/h5-8,13-14,17-18H,9-12H2,1-4H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of CMPDA

DescriptionPositive allosteric modulator of GluA2 receptors (EC50 values are 45.4 and 63.4 nM at GluA2i and GluA2o respectively, in a calcium influx screening assay). Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.

CMPDA Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

CMPDA Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of CMPDA

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6558 mL 13.2792 mL 26.5583 mL 53.1166 mL 66.3958 mL
5 mM 0.5312 mL 2.6558 mL 5.3117 mL 10.6233 mL 13.2792 mL
10 mM 0.2656 mL 1.3279 mL 2.6558 mL 5.3117 mL 6.6396 mL
50 mM 0.0531 mL 0.2656 mL 0.5312 mL 1.0623 mL 1.3279 mL
100 mM 0.0266 mL 0.1328 mL 0.2656 mL 0.5312 mL 0.664 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on CMPDA

CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor. IC50 value: 45.4 ± 4.2 nM/63.4 ± 5.6 nM(GluA2i/GluA2o) [1] Target: AMPAR modulator CMPDA was nearly equipotent at modulating the two isoforms of GluA2 receptors, whereas CMPDB displayed a modest preference for the flip splice variant. Similar to CX614, CMPDA slowed the rate of deactivation of GluA2o receptors approximately 2-fold but had no effect on GluA2i receptor deactivation [1].

References:
[1]. Timm DE, et al. Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation. Mol Pharmacol. 2011 Aug;80(2):267-80.

Featured Products
New Products
 

References on CMPDA

Targeting IkappaB Kinase beta/NF-kappaB Signaling in Human Prostate Cancer by a Novel IkappaB Kinase beta Inhibitor CmpdA.[Pubmed:27196761]

Mol Cancer Ther. 2016 Jul;15(7):1504-14.

NF-kappaB plays an important role in many types of cancer, including prostate cancer, but the role of the upstream kinase of NF-kappaB, IKKbeta, in prostate cancer has neither been fully documented nor are there any effective IKKbeta inhibitors used in clinical settings. Here, we have shown that IKKbeta activity is mediated by multiple kinases including IKKalpha in human prostate cancer cell lines that express activated IKKbeta. IHC analysis (IHC) of human prostate cancer tissue microarrays (TMA) demonstrates that phosphorylation of IKKalpha/beta within its activation loop gradually increases in low to higher stage tumors as compared with normal tissue. The expression of cell proliferation and survival markers (Ki-67, Survivin) and epithelial-to-mesenchymal transition (EMT) markers (Slug, Snail), as well as cancer stem cell (CSC)-related transcription factors (Nanog, Sox2, Oct-4), also increase in parallel among the respective TMA samples analyzed. IKKbeta, but not NF-kappaB, is found to regulate Nanog, which, in turn, modulates the levels of Oct4, Sox2, Snail, and Slug, indicating an essential role of IKKbeta in regulating CSCs and EMT. The novel IKKbeta inhibitor CMPDA inhibits constitutively activated IKKbeta/NF-kappaB signaling, leading to induction of apoptosis and inhibition of proliferation, migration, and stemness in these cells. CMPDA also significantly inhibits tumor growth in xenografts without causing apparent in vivo toxicity. Furthermore, CMPDA and docetaxel act synergistically to inhibit proliferation of prostate cancer cells. These results indicate that IKKbeta plays a pivotal role in prostate cancer, and targeting IKKbeta, including in combination with docetaxel, may be a potentially useful strategy for treating advanced prostate cancer. Mol Cancer Ther; 15(7); 1504-14. (c)2016 AACR.

Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.[Pubmed:21543522]

Mol Pharmacol. 2011 Aug;80(2):267-80.

At the dimer interface of the extracellular ligand-binding domain of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors a hydrophilic pocket is formed that is known to interact with two classes of positive allosteric modulators, represented by cyclothiazide and the ampakine 2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1,4-dioxan-10-one (CX614). Here, we present structural and functional data on two new positive allosteric modulators of AMPA receptors, phenyl-1,4-bis-alkylsulfonamide (CMPDA) and phenyl-1,4-bis-carboxythiophene (CMPDB). Crystallographic data show that these compounds bind within the modulator-binding pocket and that substituents of each compound overlap with distinct moieties of cyclothiazide and CX614. The goals of the present study were to determine 1) the degree of modulation by CMPDA and CMPDB of AMPA receptor deactivation and desensitization; 2) whether these compounds are splice isoform-selective; and 3) whether predictions of mechanism of action could be inferred by comparing molecular interactions between the ligand-binding domain and each compound with those of cyclothiazide and CX614. CMPDB was found to be more isoform-selective than would be predicted from initial binding assays. It is noteworthy that these new compounds are both more potent and more effective and may be more clinically relevant than the AMPA receptor modulators described previously.

Description

CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.

Keywords:

CMPDA,380607-77-2,Natural Products,AMPAR, buy CMPDA , CMPDA supplier , purchase CMPDA , CMPDA cost , CMPDA manufacturer , order CMPDA , high purity CMPDA

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: